Paris, December 13, 2024 – Delbert Pharma, a French pharmaceutical company dedicated to safeguarding essential medicines, announces the acquisition of the injectable aztreonam (Azactam®) molecule from Bristol Myers Squibb.
This acquisition represents a major milestone in the history of Delbert Pharma, expanding its international presence beyond Europe in the field of infectious diseases.
This acquisition includes the Marketing Authorizations (MAs), as well as the trademark, of the injectable forms of this antibiotic Azactam ®1g and Azactam® 2g in nearly 20 countries worldwide where it is marketed.
The transfer of the Marketing Authorizations will occur progressively across the different countries throughout 2025, and Bristol Myers Squibb or their local partners will remain the holders of these MAs during this transition period.
With its expertise in relocating production, Delbert Pharma will also lead the industrial transfer for the production of Azactam® and will make every effort to ensure the continuity and availability of the product for patients globally.
“This acquisition represents a significant step in our growth strategy. By adding Azactam® to our portfolio of injectable antibiotics, we strengthen our commitment to providing international access to essential treatments. This is a new chapter for Delbert Pharma, demonstrating our determination to expand our presence beyond Europe and to continue meeting essential medical needs worldwide, ” stated Eric Fidelin, Executive General Director of Delbert Pharma.
Ensuring the maintenance and development of medications whose absence could be detrimental to patients and to the balance of the healthcare systems is our core mission. The acquisition of Azactam® further strengthens Delbert Pharma’s commitment as a mission-driven company.
We thank Bristol Myers Squibb for the mutual trust shared over many years between our two companies, as Azactam is the fourth Bristol Myers Squibb product acquired by Delbert Pharma in the past decade.
About Delbert Pharma
Delbert Pharma is an independent French pharmaceutical company founded in 2013 and a mission-driven company since 2023, dedicated to preserving essential medicines for the stability of healthcare systems. Delbert Pharma offers a broad range of treatments in infectious diseases, neurology, and onco-hematology, addressing critical medical needs in Europe and beyond. The company is strongly committed to combating medicine shortages and fostering pharmaceutical reindustrialization.
About Azactam
Aztreonam (Azactam®) is an injectable antibiotic of the monobactam class, primarily used to treat severe infections caused by Gram-negative bacteria, including septicemia, urinary tract infections, skin and soft tissue infections, bronchopulmonary, intra-abdominal, and gyneco-obstetric infections. As a key therapeutic agent, Azactam® is particularly valuable given the rise in infections resistant to beta-lactam antibiotics, making the availability of alternative treatments essential..